Table 4 Total discounted direct costs, RSV-related hospitalizations, and QALYs of palivizumab vs. placebo in preterm neonates ≤ 35 wGA in Colombia, 2022
Outcome | No palivizumab | Palivizumab |
|---|---|---|
Total discounted direct costs | $ 4,056,239 | $ 2,534,193 |
RSV-related hospitalizations | 349 | 76 |
∆ Costs (palivizumab– no palivizumab) | - $ 1,522,046 | |
∆ QALYs (palivizumab– no palivizumab) | 125 | |